380 related articles for article (PubMed ID: 31965018)
1. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
[TBL] [Abstract][Full Text] [Related]
2. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
3. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds.
Xu C; Wan X; Xu L; Weng H; Yan M; Miao M; Sun Y; Xu G; Dooley S; Li Y; Yu C
J Hepatol; 2015 Jun; 62(6):1412-9. PubMed ID: 25623823
[TBL] [Abstract][Full Text] [Related]
4. Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Hirai T; Kimura T; Echizen H
Biol Pharm Bull; 2016; 39(6):1013-21. PubMed ID: 27251504
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
Lü JM; Yao Q; Chen C
Biochem Pharmacol; 2013 Nov; 86(9):1328-37. PubMed ID: 23994369
[TBL] [Abstract][Full Text] [Related]
6. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.
Yisireyili M; Hayashi M; Wu H; Uchida Y; Yamamoto K; Kikuchi R; Shoaib Hamrah M; Nakayama T; Wu Cheng X; Matsushita T; Nakamura S; Niwa T; Murohara T; Takeshita K
Sci Rep; 2017 Apr; 7(1):1266. PubMed ID: 28455534
[TBL] [Abstract][Full Text] [Related]
8. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats.
Kakimoto M; Fujii M; Sato I; Honma K; Nakayama H; Kirihara S; Fukuoka T; Ran S; Hirohata S; Kitamori K; Yamamoto S; Watanabe S
J Appl Biomed; 2023 Jun; 21(2):80-90. PubMed ID: 37376883
[TBL] [Abstract][Full Text] [Related]
11. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway.
Cho IJ; Oh DH; Yoo J; Hwang YC; Ahn KJ; Chung HY; Jeong SW; Moon JY; Lee SH; Lim SJ; Jeong IK
Sci Rep; 2021 May; 11(1):9894. PubMed ID: 33972568
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
14. Xanthine oxidase inhibition alleviates the cardiac complications of insulin resistance: effect on low grade inflammation and the angiotensin system.
El-Bassossy HM; Watson ML
J Transl Med; 2015 Mar; 13():82. PubMed ID: 25889404
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
16. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
17. Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Omizo H; Tamura Y; Morimoto C; Ueno M; Hayama Y; Kuribayashi-Okuma E; Uchida S; Shibata S
Sci Rep; 2020 Jun; 10(1):9326. PubMed ID: 32518351
[TBL] [Abstract][Full Text] [Related]
18. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
19. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
20. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
Šmelcerović A; Tomović K; Šmelcerović Ž; Petronijević Ž; Kocić G; Tomašič T; Jakopin Ž; Anderluh M
Eur J Med Chem; 2017 Jul; 135():491-516. PubMed ID: 28478180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
